Document is current
Any future updates will be listed below
-
Authors
Bislenghi, Gabriele
Ferrante, Marc
De Hertogh, Gert
Sucameli, Francesco https://orcid.org/0000-0002-6220-5728
Wolthuis, Albert
Sabino, Joao
Vermeire, Severine
D’Hoore, Andrè
- License Information
-
More Information
Article History
Received: 2 December 2021
Accepted: 14 February 2022
First Online: 27 February 2022
Declarations
:
: Marc Ferrante: Research grant: Amgen, Biogen, Janssen, Pfizer, and Takeda. Consultancy: Abbvie, Boehringer-Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Samsung Bioepis, Sandoz, Takeda, and Thermo Fisher. Speakers’ fee: Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda, and Truvion Healthcare. Severine Vermeire: Receipt of grants/research supports: MSD, Abbvie, Takeda, Janssen, Pfizer. Receipt of honoraria or consultation fees: AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, Progenity, Lilly, Arena, Gilead and Janssen. Participation in a company sponsored speaker’s bureau: AbbVie, MSD, Takeda, Ferring, Hospira, Pfizer, Janssen, and Tillots. Gert De Hertogh’s institution KULeuven receives fees for his activities as pathology central reviewer for trials of Centocor and Takeda. The authors declare no other conflicts.
